	US 11,701,326 B2
	Amlodipine formulations
Scott Brauer, Harrisionville, MO (US); and Gerold L. Mosher, Kansas City, MO (US)
Assigned to AZURITY PHARMACEUTICALS, INC., Woburn, MA (US)
Filed by Azurity Pharmaceuticals, Inc., Woburn, MA (US)
Filed on Aug. 22, 2022, as Appl. No. 17/892,738.
Application 17/892,738 is a continuation of application No. 17/067,396, filed on Oct. 9, 2020, granted, now 11,471,409.
Application 17/067,396 is a continuation of application No. PCT/US2019/027044, filed on Apr. 11, 2019.
Application PCT/US2019/027044 is a continuation of application No. 16/381,575, filed on Apr. 11, 2019, granted, now 10,799,453, issued on Oct. 13, 2020.
Claims priority of provisional application 62/656,188, filed on Apr. 11, 2018.
Prior Publication US 2022/0401363 A1, Dec. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/10 (2006.01); A61K 31/451 (2006.01); A61K 47/26 (2006.01); A61K 9/14 (2006.01); A61K 47/02 (2006.01); A61K 47/38 (2006.01); A61K 47/24 (2006.01); A61K 47/12 (2006.01)

CPC A61K 9/10 (2013.01) [A61K 9/14 (2013.01); A61K 31/451 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)]

19 Claims

1. A suspension comprising particles comprising amlodipine benzoate and having a median particle diameter D50 value of between 5 μm and 40 μm as measured by a particle size analyzer, wherein the suspension is made by mixing amlodipine besylate and sodium benzoate in an aqueous mixture between 1 minute and 1 hour, thereby forming the suspension comprising particles comprising amlodipine benzoate.